From kidney to liver: Are sodium–glucose cotransporter-2 inhibitors emerging as metabolic disease modifiers?

Figure 1 PRISMA flow diagram. HCC: Hepatocellular carcinoma.

Figure 2 Forest plot. A: The association between sodium–glucose cotransporter-2 inhibitor use and hepatocellular carcinoma incidence in adults with metabolic dysfunction–associated steatotic liver disease (primary meta-analysis of three cohort studies); B: The sensitivity analysis restricted to studies comparing sodium–glucose cotransporter-2 inhibitors with non–sodium–glucose cotransporter-2 oral hypoglycemic agents. RR: Relative risk; SGLT2: Sodium-glucose cotransporter-2.